Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT02004392
Other study ID # EVP-6124-026
Secondary ID 2013-002654-75
Status Terminated
Phase Phase 3
First received November 27, 2013
Last updated May 2, 2016
Start date June 2014
Est. completion date August 2017

Study information

Verified date September 2015
Source FORUM Pharmaceuticals Inc
Contact n/a
Is FDA regulated No
Health authority Argentina: Ministry of HealthAustralia: National Health and Medical Research CouncilBelgium: Federal Agency for Medicines and Health Products, FAMHPCanada: Health CanadaCzech Republic: State Institute for Drug ControlFrance: Agence Nationale de Sécurité du Médicament et des produits de santéGermany: Federal Institute for Drugs and Medical DevicesItaly: The Italian Medicines AgencyJapan: Ministry of Health, Labor and WelfareMexico: Ministry of HealthNetherlands: Medicines Evaluation Board (MEB)Poland: Office for Registration of Medicinal Products, Medical Devices and Biocidal ProductsSouth Africa: Medicines Control CouncilSouth Korea: Ministry of Food and Drug SafetySpain: Agencia Española de Medicamentos y Productos SanitariosUnited Kingdom: Medicines and Healthcare Products Regulatory AgencyUnited States: Food and Drug AdministrationPortugal: INFARMED, National Authority of Medicines and Health Products, IP
Study type Interventional

Clinical Trial Summary

This is a 26-week, randomized extension of the Phase 3 double-blind placebo-controlled studies, EVP-6124-024 and EVP-6124-025. In this extension study, subjects who complete study EVP-6124-024 or EVP-6124-025 and fulfill all entry criteria will be randomized to receive EVP-6124 for an additional 26 weeks.


Recruitment information / eligibility

Status Terminated
Enrollment 348
Est. completion date August 2017
Est. primary completion date August 2017
Accepts healthy volunteers No
Gender Both
Age group 55 Years to 85 Years
Eligibility Inclusion Criteria:

- Male or female subjects of any race, aged =55 and =85 years at time of entry into study EVP-6124-024 or EVP-6124-025

- Informed consent form (ICF) for this extension study signed by the subject or legally acceptable representative and an ICF signed by the support person/caregiver before initiation of any study-specific procedures

- Successful completion (Day 182) of study EVP-6124-024 or EVP-6124-025

- No clinically significant change in the judgment of the investigator in the subject's medical status during study EVP-6124-024 or EVP-6124-025

- In the judgment of the investigator, extension treatment is in the best interest of the subject

- Fertile, sexually active subjects (men and women) must use an effective method of contraception during the study. Female subjects and the female partner of male subjects must be surgically sterile (hysterectomy or bilateral tubal ligation), postmenopausal for at least 1-year, or willing to practice adequate methods of contraception if of childbearing potential (defined as consistent use of combined effective methods of contraception [including at least 1 barrier method])

- Reliable and capable support person/caregiver, who if not living in the same household, interacts with the subject approximately 4 times per week and will be available to attend clinic visits in person when possible

Exclusion Criteria:

- Significant risk of suicidal or violent behavior in the judgment of the investigator

- Adverse events from the previous study (EVP-6124-024 or EVP-6124-025) that have not resolved, are moderate or severe, judged to be possibly related or related to study drug, and considered by the investigator to be a contraindication to extension study participation

- Any condition that would make the subject in the judgment of the investigator unsuitable for the study

- Female subjects who are pregnant, nursing, or planning to become pregnant during the extension study

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Drug:
EVP-6124


Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
FORUM Pharmaceuticals Inc

Countries where clinical trial is conducted

United States,  Australia,  Belgium,  Canada,  Czech Republic,  Italy,  Korea, Republic of,  Netherlands,  Poland,  South Africa,  Spain,  United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Primary Safety of 2 fixed doses of EVP-6124 for up to 52 weeks in subjects with Alzheimer's disease who complete study EVP-6124-024 or EVP-6124-025 Criteria for evaluation include: adverse events, clinical laboratory tests, vital signs, body weight, 12-lead ECG, physical examination, concomitant medications, C-SSRS, and GDS. Baseline to Day 182 or Early Termination Yes
Secondary Change from Baseline in cognition using the Mini-Mental State Examination (MMSE) Baseline to Day 182 or Early Termination No
Secondary Change from Baseline in psychiatric and behavioral symptoms using the Neuropsychiatric Inventory (NPI) Baseline to Day 182 or Early Termination No
Secondary Change from Baseline in quality of life using the EuroQol-5D (EQ-5D) Baseline to Day 182 or Early Termination No
Secondary Pharmacoeconomic outcomes using the Resource Utilization in Dementia (RUD-Lite 3.3) Baseline to Day 182 or Early Termination No
Secondary Caregiver perceived burden using the Zarit Burden Interview (ZBI) Baseline to Day 182 or Early Termination No
See also
  Status Clinical Trial Phase
Completed NCT05686486 - Gentle Gymnastics and Relationship Between Family Caregivers and Residents With Dementia in Nursing Homes N/A
Terminated NCT05451693 - Outreach-ER: A Dementia Care Intervention Program
Recruiting NCT05820919 - Enhancing Sleep Quality for Nursing Home Residents With Dementia - R33 Phase N/A
Enrolling by invitation NCT06040294 - Dementia and Disability Simulation for College Nursing Students' Senior Activity Facilitation Skills N/A
Completed NCT05114187 - An Internet-Based Education Program for Care Partners of People Living With Dementia N/A
Recruiting NCT06322121 - Vascular Aspects in Dementia: Part 2
Active, not recruiting NCT03676881 - Longitudinal Validation of a Computerized Cognitive Battery (Cognigram) in the Diagnosis of Mild Cognitive Impairment and Alzheimer's Disease
Completed NCT04426838 - Cognitive Behavioral Therapy for Insomnia for the Dementia Caregiving Dyad N/A
Recruiting NCT03462485 - Pilot Study of the Effects of Playing Golf on People With Dementia N/A
Active, not recruiting NCT03677284 - Managing Time With Dementia: Effects of Time Assistive Products in People With Dementia N/A
Completed NCT03849937 - Changing Talk Online (CHATO) Study N/A
Recruiting NCT06284213 - Biomarkers for Vascular Contributions to Cognitive Impairment and Dementia Consortium
Recruiting NCT05579236 - Cortical Disarray Measurement in Mild Cognitive Impairment and Alzheimer's Disease
Completed NCT05080777 - Pilot Pragmatic Clinical Trial to Embed Tele-Savvy Into Health Care Systems N/A
Completed NCT04571697 - A Study of Comparing Rates of Dementia and Alzheimer's Disease in Participants Initiating Methotrexate Versus Those Initiating Anti-tumor Necrosis Factor (TNF)-Alpha Therapy
Completed NCT03583879 - Using Gait Robotics to Improve Symptoms of Parkinson's Disease N/A
Recruiting NCT06033066 - Financial Incentives and Recruitment to the APT Webstudy N/A
Active, not recruiting NCT05204940 - Longitudinal Observational Biomarker Study
Recruiting NCT05684783 - Dementia Champions in Homecare
Completed NCT03147222 - Function Focused Care: Fracture Care at Home N/A